Related Experiment Videos
Minocycline in amyotrophic lateral sclerosis: a pilot study
F E Pontieri1, A Ricci, C Pellicano
1Dipartimento di Scienze Neurologiche, II Facoltà di Medicina e Chirurgia, Università di Roma La Sapienza, Clinica Neurologica, Ospedale Sant Andrea, Via di Grottarossa 1035, I-00189 Rome, Italy. francesco.pontieri@ospedalesantandrea.it
Summary
This pilot study found that combining minocycline with riluzole is safe for amyotrophic lateral sclerosis (ALS) patients. Further research is needed to determine if this combination effectively treats ALS.
Area of Science:
- Neuroscience
- Pharmacology
- Neurology
Background:
- Minocycline demonstrates neuroprotective properties in preclinical models.
- Emerging evidence suggests minocycline as a potential therapeutic agent for amyotrophic lateral sclerosis (ALS).
- Riluzole is a current standard-of-care medication for ALS.
Purpose of the Study:
- To evaluate the safety and tolerability of combined minocycline and riluzole treatment in ALS patients.
- To assess the feasibility of administering this combination therapy over a 6-month period.
Main Methods:
- A randomized pilot study involving 20 ALS patients.
- Patients received either riluzole alone or a combination of riluzole and minocycline for 6 months.
- Disease progression was monitored using the ALS-Functional Rating Scale, and respiratory function was assessed at baseline and follow-up intervals.
Main Results:
- The combined treatment of minocycline and riluzole was well-tolerated, with no significant adverse events reported.
- Both treatment groups showed comparable disease progression and respiratory function over the 6-month study period.
Conclusions:
- Combined treatment with minocycline and riluzole appears to be safe and feasible in ALS patients.
- This pilot study supports the need for larger, randomized controlled trials to investigate the efficacy of this combination therapy for ALS.